Redeye comments on FluoGuide announcing results from the first part of the ongoing CT-005 trial eval...
Redeye comment's on Hansa Biopharma's CMD. Clinical data from imlifidase across clinical trials were...
On Thursday evening, Aiforia announced having completed a directed share issue of 3.
Redeye initiates coverage of Eolus, one of the Nordics’ most established renewable energy developers...
Välfärdsteknikbolaget Careium rider på en stark strukturell medvind, där den pågående nedsläckningen...
Vi publicerar nu den andra upplagan av Microcap Top Picks, där vi följer upp investeringscasen i de ...
Yesterday, LION released its full year report for 2025.
Redeye shares its preview of BONESUPPORT’s Q2 2026 results, due July 16.
We expect Q2 to remain a transitional quarter for Nelly.
* We forecast net sales of SEK 191m in Q2'26e * DTC could weigh on Q2 EBITA, -7% y-o-y at SEK 24m * ...
Redeye shares its preview of Xvivo’s Q2 2026 results, due on July 14.
* Q2: Sales of EUR ~37m (~36m), adj. EBIT of 3.5m (-0.
Coor väntas möta tuffa jämförelsetal i Q2-2026, särskilt i Norge där olje- och gasvolymerna var exce...
Enersense has won a contract with Aquatech to install pipelines and steel structures for the water t...
Redeye comments on the latest positive update from the NEXUS-study with ANXV.
* UK RM&I forecast cut to -8% in 2026 * We include UBC in our model, '27e EBITA +8% * We raise our f...
Enersense will install pipelines and steel structures for the water treatment plant in Boden, Sweden...
Kortsiktigt stök har sänkt tillväxtbolaget. Bakom kulisserna sker en omfattande omställning som öppn...
We expect another strong quarter in terms of sales.
Redeye comments on the interim analysis of the phase Ib/IIa study of golexanolone in primary biliary...